Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Ulcerative colitis
10 evidence topics · 9 sources
United States: 378 per 100,000 and an estimated 1.253 million people with ulcerative colitis
“The age-, sex- and insurance-standardized prevalence per 100,000 population was 721 (95% CI 717 – 726) for IBD, 378 per 100,000 (95% CI 375 – 382) for ulcerative colitis and 305 (95% CI 302 – 308) for Crohn’s disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Extrapolated to the 2020 census estimate of 331,449,281 US population, there is an estimated 2.390 million Americans with IBD, 1.253 million with ulcerative colitis and 1.011 million with Crohn’s disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, the ratio of ulcerative colitis to Crohn’s disease was higher in Asian (1.6:1) and Hispanic (1.8:1) than in White (1.2:1) or Black (1.2:1) Americans.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: prevalence per 100,000 under alternative case definitions and enrollment periods
| Prevalence definition | Minimum enrollment | Prevalence per 100,000 (95% CI) |
|---|---|---|
| Primary | 4 years | “378 (375–382)”View highlighted excerpt for this quote |
| Secondary | 4 years | “438 (435–441)”View highlighted excerpt for this quote |
| Primary | 1 year | “312 (310–314)”View highlighted excerpt for this quote |
| Secondary | 1 year | “358 (356–361)”View highlighted excerpt for this quote |
United States: prevalence exceeding 400 per 100,000 in North America
United States: Medicare fee-for-service beneficiaries
United States: moderately to severely active disease, about 22% of patients in a given year (ICER 2020, citing the Crohn's & Colitis Foundation)
Moderately to severely active disease at diagnosis: population-based inception cohorts
“In a cohort of patients diagnosed in Copenhagen county between 1962–93, disease course was characterized as indolent, moderate or aggressive in 13%, 73% and 14% of patients, respectively, within the first 5-years of diagnosis; in the same region, in a cohort of patients diagnosed between 2003–04, early disease activity was characterized as mild in 76%, and moderate-to-severe in 24% (23,24).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: company estimates of moderate-to-severe patients and advanced therapy use
United States: advanced therapy use after diagnosis in commercially insured adults, 2007 to 2023
“Among 3,893 patients with newly diagnosed UC (age at diagnosis, 41±14y; 52% male; 80% White, 7.2% Black and 8.2% Hispanic patients) followed over 4.2±3.0y, 5-year risk of IBD-related hospitalization, colectomy and serious infection was 11%, 6%, and 10%, respectively, with lower risk in Hispanic patients (vs. White patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cumulative 1- and 5y use of advanced therapy was 17% (95% CI, 15–18) and 29% (95% CI, 27–31), respectively (Table 1). In a more contemporary cohort of patients diagnosed in 2019–23, the corresponding rate was 27% (95% CI, 24–29) and 38% (95% CI, 34–41), respectively (aHR, 3.43 [95% CI, 2.86–4.13]) (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cumulative 1- and 5y use of TNF antagonists and non-TNF-targeting advanced therapy in the more contemporary cohort was 19% (95% CI, 16–21) and 26% (95% CI, 23–29), and 12% (95% CI, 10–14) and 27% (95% CI, 24–31), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global: prevalence ranges by epidemiologic stage and projected growth
“The clear distinctions across stages define the CRs for the incidence and prevalence of IBD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“stage 1: CR-I = 0.1–1.2, CR-P = 1.2–10.5; stage 2: CR-I = 3.3–10.6, CR-P = 31.2–100.5; stage 3: CR-I = 18.1–34.1, CR-P = 362.9–660.1 (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prevalence remains consistently low in regions classified as stage 1. Prevalence noticeably increases in stage 2 and then rises rapidly in stage 3 (Extended Data Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A slowing of prevalence growth rates was also observed in central difference approximations for both CD and UC (Supplementary Fig. 18c,d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote